PTC Therapeutics shares are trading lower after the company announced its MOVE-FA trial of vatiquinone did not meet its primary endpoint. The company will discontinue its preclinical and early research gene therapy programs.
Portfolio Pulse from Bill Haddad
PTC Therapeutics announced that its MOVE-FA trial of vatiquinone did not meet its primary endpoint, leading to a decline in its share price. The company will also discontinue its preclinical and early research gene therapy programs.
May 23, 2023 | 8:39 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
PTC Therapeutics shares are trading lower after the company's MOVE-FA trial of vatiquinone failed to meet its primary endpoint, and the discontinuation of its preclinical gene therapy programs.
The failure of the MOVE-FA trial to meet its primary endpoint is a significant setback for PTC Therapeutics, as it indicates that the drug may not be as effective as hoped. This, combined with the discontinuation of its preclinical gene therapy programs, could negatively impact the company's future prospects and investor confidence, leading to a decline in its share price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100